Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2021-10-20 | Forward | 4:1 |
| 2008-05-05 | Forward | 10000:5271 |
Evotec SE is a Hamburg-based global drug discovery and development partner collaborating with major pharma companies across diverse therapeutic areas.
A CDMO specializing in biologics, leveraging AI, machine learning, and continuous manufacturing to accelerate and reduce the cost of developing complex biological medicines for pharma and biotech partners.
In July 2025, Evotec SE significantly lowered its revenue forecast for the fiscal year, citing underperformance in its Shared R&D base business. The company reduced its expected revenues from a range of €840-880 million to €760-800 million, leading to a sharp decline in its stock price and raising investor concerns about its near-term growth prospects.
In a landmark transaction, Evotec SE agreed to sell its Just – Evotec Biologics manufacturing site in Toulouse, France, to Sandoz. The deal, valued at over US$650 million, includes the sale of the facility and an indefinite license to Evotec's continuous manufacturing technology, fundamentally shifting Evotec's Just - Evotec Biologics segment to a less capital-intensive, technology-licensing-focused model.
Evotec AG (NASDAQ: EVO - Get Free Report) saw unusually-strong trading volume on Monday. 143,696 shares traded hands during mid-day trading, an increase of 43% from the previous session's volume of 100,289 shares. The stock last traded at $1.5810 and had previously closed at $1.56. Analyst Ratings Changes A number of research analysts have recently commented
Evotec Announces Chief Scientific Officer TransitionPR NewswireHAMBURG, Germany, Sept. 29, 2026Dr. Cord Dohrmann to step down as of September 30, 2026Search ong
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 SYRE | $92.25 | COMPARE |
 SDGR | $32.21 | COMPARE |
 PHVS | $30.91 | COMPARE |
 ALVO | $6.18 | COMPARE |
 AZTA | $41.23 | COMPARE |
 NVCR | $15.03 | COMPARE |
 HROW | $30.74 | COMPARE |
 TDOC | $5.67 | COMPARE |
